Skip to main content

Serevent Diskus Side Effects

Generic name: salmeterol

Medically reviewed by Drugs.com. Last updated on Jul 30, 2023.

Note: This document contains side effect information about salmeterol. Some dosage forms listed on this page may not apply to the brand name Serevent Diskus.

Applies to salmeterol: inhalation powder.

Serious side effects of Serevent Diskus

Along with its needed effects, salmeterol (the active ingredient contained in Serevent Diskus) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking salmeterol:

More common

Less common

Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking salmeterol:

Symptoms of overdose

Other side effects of Serevent Diskus

Some side effects of salmeterol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to salmeterol: inhalation aerosol, inhalation aerosol with adapter, inhalation powder.

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (12%)

Common (1% to 10%): Arthralgia, articular rheumatism, muscle cramps and spasm, bone and skeletal pain, muscle pain, muscle stiffness, muscle tightness, muscle rigidity, musculoskeletal inflammation

Frequency not reported: Join pain[Ref]

Nervous system

Very common (10% or more): Headache (up to 14%)

Common (1% to 10%): Dizziness, migraines, tremor

Frequency not reported: Sinus headache, paresthesia[Ref]

Cardiovascular

Common (1% to 10%): Pallor, hypertension, palpitations

Uncommon (0.1% to 1%): Tachycardia

Very rare (less than 0.01%): Arrhythmias (including atrial fibrillation, supraventricular tachycardia, extrasystoles)

Frequency not reported: Peripheral vasodilation and a compensatory small increase in heart rate[Ref]

Dermatologic

Common (1% to 10%): Skin rashes, urticaria, photodermatitis

Frequency not reported: Contact dermatitis, eczema[Ref]

Gastrointestinal

Common (1% to 10%): Gastrointestinal signs and symptoms, nausea, vomiting, candidiasis mouth/throat, dental discomfort and pain, dyspeptic symptoms, gastrointestinal infections, hyposalivation

Frequency not reported: Oral mucosal abnormality[Ref]

Hepatic

Common (1% to 10%): Transient elevation of hepatic enzymes[Ref]

Metabolic

Common (1% to 10%): Hyperglycemia

Rare (less than 0.1%): Hypokalemia[Ref]

Ocular

Common (1% to 10%): Conjunctivitis, keratitis[Ref]

Other

Common (1% to 10%): Influenza, ear signs and symptoms, edema and swelling

Frequency not reported: Localized aches and pains, pyrexia of unknown origin[Ref]

Psychiatric

Common (1% to 10%): Anxiety

Uncommon (0.1% to 1%): Nervousness

Rare (less than 0.1%): Insomnia

Frequency not reported: Sleep disturbances[Ref]

Respiratory

Common (1% to 10%): Nasal/sinus congestion, rhinitis, asthma, tracheitis/bronchitis, pharyngitis, sinusitis, upper respiratory tract infection, cough, throat irritation, lower respiratory signs and symptoms

Very rare (less than 0.01%): Paradoxical bronchospasm, non specific chest pain, oropharyngeal irritation

Frequency not reported: Bronchospasm

Postmarketing reports: Upper airway symptoms of laryngeal spasm, irritation, or swelling such as stridor or choking[Ref]

Hypersensitivity

Very rare (less than 0.01%): Anaphylactic reactions including edema and angioedema, bronchospasm and anaphylactic shock

Frequency not reported: Immediate hypersensitivity reactions

Postmarketing reports: Anaphylaxis[Ref]

References

1. D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI (1994) "Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma." JAMA, 271, p. 1412-6

2. Kemp JP, Bierman CW, Cocchetto DM (1993) "Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring." Ann Allergy, 70, p. 316-22

3. Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, Dockhorn RJ, Grossman J, Liddle RF, Yancey SW, et al. (1992) "A comparison of salmeterol with albuterol in the treatment of mild-to- moderate asthma." N Engl J Med, 327, p. 1420-5

4. Meyer JM, Wenzel CL, Kradjan WA (1993) "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother, 27, p. 1478-87

5. Maconochie JG, Minton NA, Chilton JE, Keene ON (1994) "Does tachyphylaxis occur to the non-pulmonary effects of salmeterol?" Br J Clin Pharmacol, 37, p. 199-204

6. Brogden RN, Faulds D (1991) "Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease." Drugs, 42, p. 895-912

7. Britton MG, Earnshaw JS, Palmer JB (1992) "A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group [published erratum appears in Eur Respir J 1993;6(1):150]." Eur Respir J, 5, p. 1062-7

8. Ullman A, Svedmyr N (1988) "Salmeterol comparison with salbutamol in adult asthmatic patients." Thorax, 43, p. 674-8

9. (1994) "Salmeterol." Med Lett Drugs Ther, 36, p. 37-9

10. "Product Information. Serevent (salmeterol)." Glaxo Wellcome

11. Mann RD, Kubota K, Pearce G, Wilton L (1996) "Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients." J Clin Epidemiol, 49, p. 247-50

12. Cerner Multum, Inc. "UK Summary of Product Characteristics."

13. Cerner Multum, Inc. "Australian Product Information."

14. Maconochie JG, Forster JK (1992) "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol, 33, p. 342-5

15. Lopezguillen A, Marques L, Lopezllorente MT, Pastor E, Figueras A (1994) "Salmeterol-induced vertigo." Eur Respir J, 7, p. 2089-90

16. Tranfa CME, Pelaia G, Grembiale RD, Naty S, Durante S, Borrello G (1998) "Short-term cardiovascular effects of salmeterol." Chest, 113, p. 1272-6

17. Svedmyr N, Lofdahl CG (1996) "The use of beta(2)-adrenoceptor agonists in the treatment of bronchial asthma." Pharmacol Toxicol, 78, p. 3-11

18. Booth H, Bish R, Walters J, Whitehead F, Walters EH (1996) "Salmeterol tachyphylaxis in steroid treated asthmatic subjects." Thorax, 51, p. 1100-4

19. Wilkinson JR, Roberts JA, Bradding P, Holgate ST, Howarth PH (1992) "Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler." BMJ, 305, p. 931-2

20. Clark CE, Ferguson AD, Siddorn JA (1993) "Respiratory arrests in young asthmatics on salmeterol." Respir Med, 87, p. 227-8

21. Dottorini ML, Tantucci C, Peccini F, Grassi V, Sorbini CA (1996) "Diurnal change of bronchial caliber and airway responsiveness in asthmatics during long-term treatment with long-acting beta 2-agonist salmeterol." Int J Clin Pharmacol Ther, 34, p. 438-43

22. Hatton MQ, Allen MB, Mellor EJ, Cooke NJ (1991) "Salmeterol rash ." Lancet, 337, p. 1169-70

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.